Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference
Rhea-AI Summary
Passage Bio (NASDAQ: PASG), a clinical-stage genetic medicines company specializing in neurodegenerative diseases, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City.
CEO Will Chou, M.D., will deliver a company overview presentation and the management team will engage in one-on-one investor meetings. The presentation will be available via video webcast to conference attendees starting September 5, 2025, at 7:00 a.m. ET, with a 30-day replay period accessible through the company's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, PASG declined 1.99%, reflecting a mild negative market reaction. This price movement removed approximately $460K from the company's valuation, bringing the market cap to $23M at that time.
Data tracked by StockTitan Argus on the day of publication.
PHILADELPHIA, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that management will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held from September 8-10, 2025 in New York City.
Will Chou, M.D., president and chief executive officer, will present an overview of the company, and management will participate in one-on-one meetings with investors. A video webcast of the presentation will be available to registered conference attendees via the conference platform beginning Friday, September 5, 2025, at 7:00 a.m. ET and will be available on the Investors & News section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the event.
About Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression.
To learn more about Passage Bio and our steadfast commitment to protecting patients and families against loss in neurodegenerative conditions, please visit: passagebio.com.
For further information, please contact:
Investors:
Stuart Henderson
Passage Bio
shenderson@passagebio.com
Passage Bio Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312.961.2502
mikebeyer@sambrown.com
FAQ
When is Passage Bio presenting at the H.C. Wainwright Conference 2025?
Who will be presenting for Passage Bio (PASG) at the H.C. Wainwright Conference?
How can investors access Passage Bio's H.C. Wainwright Conference presentation?
What is Passage Bio's (PASG) main business focus?
